Skip to content
    Clinical Trials

    Phase II ETER200 Trial: Benmelstobart Plus Anlotinib in Advanced Non-MSI-H/pMMR Endometrial Cancer

    Liang et alMedComm

    Phase II ETER200 Trial: Benmelstobart Plus Anlotinib in Advanced Non-MSI-H/pMMR Endometrial Cancer
    Patients with advanced endometrial cancer (EC) face a poor prognosis and limited therapeutic options following progression on prior systemic chemotherapy. In the multi-cohort Phase II ETER200 study (NCT04574284), investigators evaluated therapeutic regimens based on MSI/MMR status among patients with metastatic or recurrent EC who had received at least one prior chemotherapy regimen. Patients were allocated to receive benmelstobart plus anlotinib every 3 weeks (Cohort 1), benmelstobart monotherapy (Cohort 2), or anlotinib monotherapy (Cohort 3). The primary endpoint was objective response rate (ORR) assessed by an independent review committee (IRC) per RECIST v1.1.
    In the reported Cohort 1 expansion stage, 85 of the 107 enrolled patients with non-MSI-H/pMMR EC were included in the primary efficacy analysis as of May 9, 2024. The IRC-assessed ORR was 34.1% (95% CI, 24.2–45.2), and the median duration of response was 15.2 months (95% CI, 6.9–not evaluable). Median progression-free survival reached 8.8 months (95% CI, 5.8–15.2), and median overall survival was 21.8 months (95% CI, 19.5–29.1). Regarding safety, grade ≥ 3 treatment-related adverse events were reported in 69.2% of patients, with hypertension (21.2%) and palmar-plantar erythrodysesthesia syndrome (9.4%) being the most frequent. The study authors concluded that benmelstobart plus anlotinib showed promising anti-tumor activity and an acceptable safety profile, supporting further evaluation of the combination in randomized Phase III trials.

    Key Takeaways

    • In patients with advanced non-MSI-H/pMMR endometrial cancer, benmelstobart plus anlotinib achieved an independent review committee-assessed objective response rate of 34.1% (95% CI, 24.2–45.2) with a median duration of response of 15.2 months (95% CI, 6.9–not evaluable).
    • The combination resulted in a median progression-free survival of 8.8 months (95% CI, 5.8–15.2) and a median overall survival of 21.8 months (95% CI, 19.5–29.1).
    • Grade ≥ 3 treatment-related adverse events occurred in 69.2% of patients, most commonly hypertension (21.2%) and palmar-plantar erythrodysesthesia syndrome (9.4%).